Average concentrations (Min-Max) measured during the observation period (14 months) for 15 relevant compounds (ng L−1) and VF removal efficiencies (%), N=12
| Compound . | IN VF (ng L−1) . | EF VF (ng L−1) . | Elimination VF (%) . |
|---|---|---|---|
| Carbamazepine | 529 (96–1,290) | 6 (4–13) | 98 |
| Clarithromycin | 276 (61–583) | 14 (3–43) | 95 |
| Ciprofloxacin | 218 (147–357) | 36 (5–178) | 92 |
| Diclofenac | 1,523 (481–2,508) | 11 (4–31) | 99 |
| Lidocaine | 122 (32–231) | 4 (3–20) | 97 |
| Metoprolol | 363 (202–720) | 24 (5–80) | 93 |
| Propranolol | 131 (31–265) | 13 (5–42) | 88 |
| N-acetyl sulfamethoxazole | 10 (4–28) | 4 (3–5) | 45 |
| Sulfamethoxazole | 79 (18–176) | 5 (4–7) | 89 |
| Benzotriazole | 2,337 (1,049–3,493) | 17 (8–39) | 99 |
| TCPP | 3,002 (1,076–5,218) | 2,075 (707–5,761) | 26 |
| Tolyltriazole | 1,000 (505–1,337) | 11 (4–41) | 99 |
| Glyphosate | 127 (60–193) | 19 (5–49) | 85 |
| AMPA | 4,079 (1,500–9,460) | 2,634 (66–5,720) | 25 |
| PFOS | 61 (5–246) | 19 (5–67) | 62 |
| Compound . | IN VF (ng L−1) . | EF VF (ng L−1) . | Elimination VF (%) . |
|---|---|---|---|
| Carbamazepine | 529 (96–1,290) | 6 (4–13) | 98 |
| Clarithromycin | 276 (61–583) | 14 (3–43) | 95 |
| Ciprofloxacin | 218 (147–357) | 36 (5–178) | 92 |
| Diclofenac | 1,523 (481–2,508) | 11 (4–31) | 99 |
| Lidocaine | 122 (32–231) | 4 (3–20) | 97 |
| Metoprolol | 363 (202–720) | 24 (5–80) | 93 |
| Propranolol | 131 (31–265) | 13 (5–42) | 88 |
| N-acetyl sulfamethoxazole | 10 (4–28) | 4 (3–5) | 45 |
| Sulfamethoxazole | 79 (18–176) | 5 (4–7) | 89 |
| Benzotriazole | 2,337 (1,049–3,493) | 17 (8–39) | 99 |
| TCPP | 3,002 (1,076–5,218) | 2,075 (707–5,761) | 26 |
| Tolyltriazole | 1,000 (505–1,337) | 11 (4–41) | 99 |
| Glyphosate | 127 (60–193) | 19 (5–49) | 85 |
| AMPA | 4,079 (1,500–9,460) | 2,634 (66–5,720) | 25 |
| PFOS | 61 (5–246) | 19 (5–67) | 62 |